Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan for acute heart failure after acute myocardial infarction
ChiCTR2100045062Phase 4Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levosimendan and dobutamine in Acute Heart Failure (AHF), myocardial infarction (MI) and cardiogenic shock (4 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: Clinical score, Proteomics testing and 3 more. Started May 2021; status: recruiting.
02
Drugs
levosimendandobutamine
03
Conditions
Acute Heart Failure (AHF)myocardial infarction (MI)cardiogenic shock
Beyond the preview
Go deeper on ChiCTR2100045062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045062.